Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Assets (2016 - 2025)

Rein Therapeutics filings provide 10 years of Non-Current Assets readings, the most recent being $19.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 59.14% year-over-year to $19.8 million, compared with a TTM value of $168.5 million through Dec 2025, down 45.05%, and an annual FY2025 reading of $19.8 million, down 59.14% over the prior year.
  • Non-Current Assets hit $19.8 million in Q4 2025 for Rein Therapeutics, down from $48.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $87.7 million in Q4 2023, with the low at $29000.0 in Q3 2023.
  • Median Non-Current Assets over the past 5 years was $363000.0 (2021), compared with a mean of $28.3 million.
  • The sharpest move saw Non-Current Assets crashed 94.81% in 2021, then soared 294841.38% in 2024.
  • Year by year, Non-Current Assets stood at $304000.0 in 2021, then tumbled by 55.92% to $134000.0 in 2022, then soared by 65379.1% to $87.7 million in 2023, then crashed by 44.69% to $48.5 million in 2024, then tumbled by 59.14% to $19.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $19.8 million, $48.5 million, and $50.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.